CN104288655A - 一种阿里红咳喘片的制备方法及其在抑制小鼠畸胎瘤细胞f9细胞增殖药物中的应用 - Google Patents
一种阿里红咳喘片的制备方法及其在抑制小鼠畸胎瘤细胞f9细胞增殖药物中的应用 Download PDFInfo
- Publication number
- CN104288655A CN104288655A CN201410549220.XA CN201410549220A CN104288655A CN 104288655 A CN104288655 A CN 104288655A CN 201410549220 A CN201410549220 A CN 201410549220A CN 104288655 A CN104288655 A CN 104288655A
- Authority
- CN
- China
- Prior art keywords
- preparation
- extraction
- cough
- fomitopsis officinalis
- officinalis cough
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010011224 Cough Diseases 0.000 title claims abstract description 44
- 208000006673 asthma Diseases 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 230000004663 cell proliferation Effects 0.000 title claims abstract description 10
- 230000002401 inhibitory effect Effects 0.000 title abstract description 4
- 241000123326 Fomes Species 0.000 title abstract 7
- 206010043276 Teratoma Diseases 0.000 title abstract 2
- 238000000194 supercritical-fluid extraction Methods 0.000 claims abstract description 17
- 238000000874 microwave-assisted extraction Methods 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 53
- 241000408172 Fomitopsis officinalis Species 0.000 claims description 49
- 238000000605 extraction Methods 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 19
- 239000000284 extract Substances 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 13
- 235000013399 edible fruits Nutrition 0.000 claims description 8
- 208000001608 teratocarcinoma Diseases 0.000 claims description 7
- 244000141353 Prunus domestica Species 0.000 claims description 6
- 235000011435 Prunus domestica Nutrition 0.000 claims description 6
- 229940126678 chinese medicines Drugs 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 5
- 230000000274 adsorptive effect Effects 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 abstract description 11
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 abstract description 11
- 229960004949 glycyrrhizic acid Drugs 0.000 abstract description 11
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 abstract description 11
- 239000001685 glycyrrhizic acid Substances 0.000 abstract description 11
- 235000019410 glycyrrhizin Nutrition 0.000 abstract description 11
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract description 11
- 239000000463 material Substances 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 241000234653 Cyperus Species 0.000 abstract 1
- 235000002848 Cyperus flabelliformis Nutrition 0.000 abstract 1
- 240000002943 Elettaria cardamomum Species 0.000 abstract 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 abstract 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 abstract 1
- 235000002598 Inula helenium Nutrition 0.000 abstract 1
- 244000116484 Inula helenium Species 0.000 abstract 1
- 235000014676 Phragmites communis Nutrition 0.000 abstract 1
- 240000004760 Pimpinella anisum Species 0.000 abstract 1
- 235000012550 Pimpinella anisum Nutrition 0.000 abstract 1
- 235000005300 cardamomo Nutrition 0.000 abstract 1
- 235000021018 plums Nutrition 0.000 abstract 1
- 229960004756 ethanol Drugs 0.000 description 20
- 238000000034 method Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 6
- 239000013558 reference substance Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 229960000935 dehydrated alcohol Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 229920002334 Spandex Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000010165 autogamy Effects 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004900 laundering Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000004759 spandex Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 238000009923 sugaring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明属于中药技术领域,具体涉及一种阿里红咳喘片的制备方法及应用。本发明的阿里红咳喘片的制备方法,由阿里红20g、洋李100g、芦根80g、甘草60g、麻黄50g、木香30g、洋茴香120g、香附30g、豆蔻20g作为原料药制成,采用超临界萃取和微波萃取制备而成,使得甘草酸含量有很大提高。本发明还提供了阿里红咳喘片在制备抑制小鼠畸胎瘤细胞F9细胞增殖药物中的应用。
Description
技术领域
本发明属于中药技术领域,具体涉及一种阿里红咳喘片的制备方法及其在抑制小鼠畸胎瘤细胞F9细胞增殖药物中的应用。
背景技术
阿里红咳喘口服液标准号WS-10245(ZD-0245)-2002,记载于国家中成药标准汇编内科肺系分册。由阿里红20g、洋李100g、芦根80g、甘草60g、麻黄50g、木香30g、洋茴香120g、香附30g、豆蔻20g作为原料药制成,具有止咳,平喘,祛痰的功效。用于寒性咳嗽,咯痰不爽,急慢性支气管炎、哮喘。
现有技术中,尚未有阿里红咳喘口服液在提取制备方面采用超临界萃取和微波提取技术的报道,而挥发油提取,水加热提取的方法,工艺粗糙、落后,杂质多,导致患者用量很大,不方便服用,严重影响了本品在临床上应用。
发明内容
为了解决上述的技术问题,本发明提供了一种阿里红咳喘片的制备方法。
本发明的另一个目的在于提供一种阿里红咳喘片在制备抑制小鼠畸胎瘤细胞F9细胞增殖药物中的应用。
本发明的目的是通过如下的方案实现的:
一种阿里红咳喘片的制备方法,由阿里红20g、洋李100g、芦根80g、甘草60g、麻黄50g、木香30g、洋茴香120g、香附30g、豆蔻20g作为原料药制成,所述的制备方法由下列步骤组成:取洋茴香、麻黄、木香、香附、豆蔻,加入到CO2超临界萃取器中,乙醇作为夹带剂,夹带剂占总萃取溶剂的体积百分比为4-6%,萃取压力15-30MPa,温度30-50℃,CO2流量l-3ml/g生药·min,萃取时间150-200min,得超临界萃取物,备用;取其余中药,粉碎,加入3L的70%乙醇,投入微波萃取装置中进行微波萃取,萃取功率600-800W,萃取2次,每次5-10分钟,合并萃取液,浓缩,加到Dl01大孔吸附树脂柱上,50%乙醇洗脱,收集5倍量柱体积洗脱液,减压回收乙醇,浓缩并干燥,得微波提取物,备用;将上述超临界萃取物和微波提取物混合,加入淀粉,70%乙醇制颗粒,干燥,压片,制成200片,每片重0.3g。
优选的,上述的阿里红咳喘片的制备方法中,所述CO2超临界萃取中夹带剂占总萃取溶剂的体积百分比为5%。
优选的,上述的阿里红咳喘片的制备方法中,所述CO2超临界萃取中萃取压力为25MPa。
优选的,上述的阿里红咳喘片的制备方法中,所述CO2超临界萃取中萃取温度为40℃。
优选的,上述的阿里红咳喘片的制备方法中,所述CO2超临界萃取中CO2流量2ml/g生药·min。
优选的,上述的阿里红咳喘片的制备方法中,所述CO2超临界萃取中萃取时间为180min。
优选的,上述的阿里红咳喘片的制备方法中,所述微波萃取功率为700W。
优选的,上述的阿里红咳喘片的制备方法中,所述微波萃取每次萃取时间为8分钟。
上述的阿里红咳喘片在制备抑制小鼠畸胎瘤细胞F9细胞增殖药物中的应用。
现有技术中,阿里红咳喘口服液每次10ml,一日3次。阿里红咳喘口服液因其是口服液,味道较苦,不适宜小儿服用,另外,如果调味需要加糖比较多,不适糖尿病人服用,患者依从性差。采用本发明方法制备成的阿里红咳喘片每片重0.3g,每次仅需2片,一日服用3次。在具有更多活性成分的条件下大大减少了服用量。此结论可以通过下述试验证明。且制备成片剂,患者随水吞下即可,服药量小且无苦味,患者易于接受。
试验一、不同方法制备的阿里红咳喘片中甘草酸含量的比较
l、仪器及试药本发明阿里红咳喘片:按实施例1方法制备,使用560g原料药,经提取制成200片,每片重0.3g。原阿里红咳喘口服液,按照WS-10245(ZD-0245)-2002标准方法制备。Agilent1200高效液相色谱仪;METTLER AE240电子分析天平;甘草酸对照品(中国药品生物制品检定所)。
2、方法
照高效液相色谱法(中国药典2010年版一部附录ⅥD)测定。
色谱条件与系统适用性试验用十八烷基键合硅胶为填充剂;甲醇-0.2mol/L醋酸铵溶液-冰醋酸(67∶33∶1)为流动相;检测波长为250nm。理论板数按甘草酸单铵盐峰计算应不低于2000。
对照品溶液的制备精密称取甘草酸单铵盐对照品10mg,置50ml量瓶中,用流动相溶解并稀释至刻度,摇匀,即得(每1ml含甘草酸单铵盐对照品0.2mg,折合甘草酸为0.1959mg)。
本发明阿里红咳喘片供试品溶液的制备取本发明的阿里红咳喘片,研细,取0.6g,精密称定,置具塞锥形瓶中,加水10ml使溶解,溶液滤过,精密量取2ml滤液,移至蒸发皿中,蒸干,残渣加流动相使溶解,移至10ml量瓶中,加流动相至刻度,即得。
对照产品供试品溶液的制备取对照的阿里红咳喘口服液,精密量取2ml,移至蒸发皿中,蒸干,残渣加流动相使溶解,移至10ml量瓶中,加流动相至刻度,即得。
测定法分别精密吸取对照品溶液与供试品溶液各10μl,注入液相色谱仪,测定,摇匀,即得。
3、结果
结果表明,本发明阿里红咳喘片中甘草酸的含量为3.6-7.2mg/片;而原阿里红咳喘口服液中甘草酸的含量为0.36mg/ml,每次服用量2片的甘草酸含量为原口服液剂含量的2-4倍,在服用量减少的情况下,甘草酸含量有很大提高。
上述研究表明,采用本发明制备方法制备的阿里红咳喘片,有效成分含量远远高于WS-10245(ZD-0245)-2002标准记载的方法制备的阿里红咳喘口服液。
具体实施方式
下面结合具体实施例对本发明作更进一步的说明,以便本领域的技术人员更了解本发明,但不应将此理解为本发明上述主题的范围仅限于以下的实例,凡基于本发明上述内容所实现的技术均属于本发明的范围。
实施例1
取阿里红20g、洋李100g、芦根80g、甘草60g、麻黄50g、木香30g、洋茴香120g、香附30g、豆蔻20g,将透骨草、五气朝阳草、姜黄加入到CO2超临界萃取器中,乙醇作为夹带剂,夹带剂占总萃取溶剂的体积百分比为5%,萃取压力25MPa,温度40℃,CO2流量2ml/g生药·min,萃取时间180min,得超临界萃取物,备用;取其余中药,粉碎,加入3L的70%乙醇,投入微波萃取装置中进行微波萃取,萃取功率700W,萃取2次,每次8分钟,合并萃取液,浓缩,加到Dl01大孔吸附树脂柱上,50%乙醇洗脱,收集5倍量柱体积洗脱液,减压回收乙醇,浓缩并干燥,得微波提取物,备用;将上述超临界萃取物和微波提取物混合,加入淀粉,70%乙醇制颗粒,干燥,压片,制成200片,每片重0.3g。
经检测,成品中甘草酸的含量为7.25mg/片。
实施例2
取阿里红20g、洋李100g、芦根80g、甘草60g、麻黄50g、木香30g、洋茴香120g、香附30g、豆蔻20g,将透骨草、五气朝阳草、姜黄加入到CO2超临界萃取器中,乙醇作为夹带剂,夹带剂占总萃取溶剂的体积百分比为4%,萃取压力30MPa,温度50℃,CO2流量3ml/g生药·min,萃取时间150min,得超临界萃取物,备用;取其余中药,粉碎,加入3L的70%乙醇,投入微波萃取装置中进行微波萃取,萃取功率600W,萃取2次,每次5分钟,合并萃取液,浓缩,加到Dl01大孔吸附树脂柱上,50%乙醇洗脱,收集5倍量柱体积洗脱液,减压回收乙醇,浓缩并干燥,得微波提取物,备用;将上述超临界萃取物和微波提取物混合,加入淀粉,70%乙醇制颗粒,干燥,压片,制成200片,每片重0.3g。
经检测,成品中甘草酸的含量为4.52mg/片。
实施例3
取阿里红20g、洋李100g、芦根80g、甘草60g、麻黄50g、木香30g、洋茴香120g、香附30g、豆蔻20g,将透骨草、五气朝阳草、姜黄加入到CO2超临界萃取器中,乙醇作为夹带剂,夹带剂占总萃取溶剂的体积百分比为6%,萃取压力15MPa,温度30℃,CO2流量1ml/g生药·min,萃取时间200min,得超临界萃取物,备用;取其余中药,粉碎,加入3L的70%乙醇,投入微波萃取装置中进行微波萃取,萃取功率800W,萃取2次,每次10分钟,合并萃取液,浓缩,加到Dl01大孔吸附树脂柱上,50%乙醇洗脱,收集5倍量柱体积洗脱液,减压回收乙醇,浓缩并干燥,得微波提取物,备用;将上述超临界萃取物和微波提取物混合,加入淀粉,70%乙醇制颗粒,干燥,压片,制成200片,每片重0.3g。
经检测,成品中甘草酸的含量为3.68mg/片。
实施例4:阿里红咳喘片抑制小鼠畸胎瘤细胞F9细胞增殖的实验研究资料
1.实验材料
1.1实验用细胞株
小鼠畸胎瘤细胞F9细胞,山东大学实验室细胞库,DMEM+10%FBS常规培养。
1.2实验药物
研究药物:本发明阿里红咳喘片:按实施例1方法制备。
药液储液:称取100mg阿里红咳喘片,溶于5ml无水乙醇中,0.2μm滤器过滤,
500μldoff管分装,-20℃存储,同时0.2μm滤器过滤无水乙醇以备对照组之用。
1.3实验试剂
DMEM(GIBCO公司Cat.No.12100-061 Lot.No.758137);胎牛血清(浙江天杭生物科技有限公司Lot.No.100419);NaHC03(上海久亿化学试剂有限公司Cat.No.11810-033 Lot.No.1088387);Trypsin(AMRESCO公司);EDTA(AMRESCO公司);Penicillin G Sodium Salt(AMRESCO公司1);Streptomycin Sulfate(AMRESCO);无水乙醇(淄博亚杜兰经贸有限公司);MTT(Biosharp批号:0793):PBS(实验室自配);
1.4实验器材
莱卡倒置显微镜(德国Leica型号:DMIL);可见-紫外光微孔板检测仪(美国MD公司型号:SPECTRAMAX 190);C02培养箱(FORMA型号:3111);超净台(苏净集团安泰公司制造型号:SW-CJ-ZFD);纯水仪(美国Sprlng公司型号:S/N 020579);精密移液器(法国吉尔森公司型号:P2);电子天平(德国赛多利斯有限公司型号:BT323S);全自动高压灭菌锅(日本SANYO公司型号:MLS-3020);台式电热鼓风干燥箱(上海精密实验设备公司型号:DHG9123A);冰箱(西门子公司型号:KG18V21TI);液氮罐(CBS型号:2001);低速离心机(上海安亭科学仪器厂型号:KA-1000);0.2μm滤器(MILLIPORE型号:SLGP033RB);1cm培养皿(NEST公司)、96孔培养板(NEST公司);细胞计数板;离心管、移液管、Tips若干。
2.实验方法
1)F9细胞用DMEM+10%FBS于37℃、5%C02进行常规培养(10cm培养皿),当细胞生长至对数期时,收集细胞,弃去培养液,PBS轻洗3遍,加入3ml 0.25%胰蛋白酶-0.04%EDTA,37℃消化2min后,向其中加入5ml完全培养基中和反应,吹打细胞后将其转入离心管中,1000rpm离心5min,调整细胞悬液浓度3×104个/ml。
2)将细胞种入96孔培养板中,每孔加入细胞悬液180μl,培养板放入细胞培养箱中(37℃,5%C02)常规培养。
3)根据细胞生长情况,一般长至50%-70%,加入阿里红咳喘片溶液,继续培养24h。
4)24h后加入20μl MTT溶液(5mg/ml,即0.5%MTT),继续培养4h。
5)4h后扣板法倒去上清,用吸水纸轻轻拍干,每孔如入200μl二甲基亚砜,置摇床上低速振荡10min,使结晶物充分溶解。在酶联免疫检测仪490nm处测量各孔的吸光值。
6)同时设置本底(不加细胞,只加培养液),对照孔(细胞、相同浓度的药物溶解介质、培养液、MTT、二甲基亚砜),每组设定6个复孔。
7)结果以药物对细胞的抑制率表示:细胞增值抑制率(%)=(对照孔OD值-给药孔OD值)、对照孔OD值×100%。实验重复3次。
3.统计处理
采用Microsoft Excel 2007软件中的相关分析和Student t检验,数据以mean±S.D.表示。
4.实验结果
MTT法实验后统计结果显示,与对照组比较,当剂量达到5mg/ml时,对F9细胞增殖抑制有差异(P<0.05),剂量在10mg/ml时该差异具有显著性(P<0.01),当剂量达到15-20mg/ml时有极显著性差异(P<0.001)。
表1阿里红咳喘片对F9细胞增殖抑制影响研究(X±SD)
组别 | 药物浓度(mg/ml) | 抑制率(%) |
对照组 | 0 | 0 |
1 | 5 | 9.42±6.54 |
2 | 10 | 17.76±12.03* |
3 | 15 | 35.78±14.19** |
4 | 20 | 47.44±16** |
注:与对照组比较,*P<O.01;**P<0.001。
5.实验结论
本发明的阿里红咳喘片可以抑制F9细胞增殖,减少F9细胞的细胞生长数目,该作用呈剂量依赖性。
Claims (9)
1.一种阿里红咳喘片的制备方法,由阿里红20g、洋李100g、芦根80g、甘草60g、麻黄50g、木香30g、洋茴香120g、香附30g、豆蔻20g作为原料药制成,其特征在于,所述的制备方法由下列步骤组成:取洋茴香、麻黄、木香、香附、豆蔻,加入到CO2超临界萃取器中,乙醇作为夹带剂,夹带剂占总萃取溶剂的体积百分比为4-6%,萃取压力15-30MPa,温度30-50℃,CO2流量l-3ml/g生药·min,萃取时间150-200min,得超临界萃取物,备用;取其余中药,粉碎,加入3L的70%乙醇,投入微波萃取装置中进行微波萃取,萃取功率600-800W,萃取2次,每次5-10分钟,合并萃取液,浓缩,加到Dl01大孔吸附树脂柱上,50%乙醇洗脱,收集5倍量柱体积洗脱液,减压回收乙醇,浓缩并干燥,得微波提取物,备用;将上述超临界萃取物和微波提取物混合,加入淀粉,70%乙醇制颗粒,干燥,压片,制成200片,每片重0.3g。
2.根据权利要求l所述的阿里红咳喘片的制备方法,其特征在于,所述CO2超临界萃取中夹带剂占总萃取溶剂的体积百分比为5%。
3.根据权利要求l所述的阿里红咳喘片的制备方法,其特征在于,所述CO2超临界萃取中萃取压力为25 MPa。
4.根据权利要求l所述的阿里红咳喘片的制备方法,其特征在于,所述CO2超临界萃取中萃取温度为40℃。
5.根据权利要求l所述的阿里红咳喘片的制备方法,其特征在于,所述CO2超临界萃取中CO2流量2ml/g生药·min。
6.根据权利要求l所述的阿里红咳喘片的制备方法,其特征在于,所述CO2超临界萃取中萃取时间为180min。
7.根据权利要求l所述的阿里红咳喘片的制备方法,其特征在于,所述微波萃取功率为700W。
8.根据权利要求l所述的阿里红咳喘片的制备方法,其特征在于,所述微波萃取每次萃取时间为8分钟。
9.权利要求l所述的阿里红咳喘片在制备抑制小鼠畸胎瘤细胞F9细胞增殖药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410549220.XA CN104288655A (zh) | 2014-10-16 | 2014-10-16 | 一种阿里红咳喘片的制备方法及其在抑制小鼠畸胎瘤细胞f9细胞增殖药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410549220.XA CN104288655A (zh) | 2014-10-16 | 2014-10-16 | 一种阿里红咳喘片的制备方法及其在抑制小鼠畸胎瘤细胞f9细胞增殖药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104288655A true CN104288655A (zh) | 2015-01-21 |
Family
ID=52308766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410549220.XA Pending CN104288655A (zh) | 2014-10-16 | 2014-10-16 | 一种阿里红咳喘片的制备方法及其在抑制小鼠畸胎瘤细胞f9细胞增殖药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104288655A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1138475A (zh) * | 1996-01-22 | 1996-12-25 | 刘勇民 | 一种治疗咳喘的药物及其制作方法 |
CN101721434A (zh) * | 2008-10-22 | 2010-06-09 | 周亚伟 | 一种阿里红有效组分及其制备方法和用途 |
CN103705825A (zh) * | 2013-12-30 | 2014-04-09 | 孙亚平 | 铁帚清浊片在制备抑制畸胎瘤细胞f9细胞增殖药物中的应用 |
CN103751424A (zh) * | 2013-12-06 | 2014-04-30 | 济南新起点医药科技有限公司 | 一种青梅感冒片的制备方法及其在抑制畸胎瘤细胞f9细胞增殖药物中的应用 |
CN103800871A (zh) * | 2013-12-10 | 2014-05-21 | 济南新起点医药科技有限公司 | 止眩安神片在制备抑制畸胎瘤细胞f9细胞增殖药物中的应用 |
-
2014
- 2014-10-16 CN CN201410549220.XA patent/CN104288655A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1138475A (zh) * | 1996-01-22 | 1996-12-25 | 刘勇民 | 一种治疗咳喘的药物及其制作方法 |
CN101721434A (zh) * | 2008-10-22 | 2010-06-09 | 周亚伟 | 一种阿里红有效组分及其制备方法和用途 |
CN103751424A (zh) * | 2013-12-06 | 2014-04-30 | 济南新起点医药科技有限公司 | 一种青梅感冒片的制备方法及其在抑制畸胎瘤细胞f9细胞增殖药物中的应用 |
CN103800871A (zh) * | 2013-12-10 | 2014-05-21 | 济南新起点医药科技有限公司 | 止眩安神片在制备抑制畸胎瘤细胞f9细胞增殖药物中的应用 |
CN103705825A (zh) * | 2013-12-30 | 2014-04-09 | 孙亚平 | 铁帚清浊片在制备抑制畸胎瘤细胞f9细胞增殖药物中的应用 |
Non-Patent Citations (6)
Title |
---|
国家药品监督管理局: "《国家药品标准(试行)颁布件》", 1 December 2002 * |
孙志慧: "《饮食宜忌与食物搭配大全》", 31 March 2014, 天津科学技术出版社 * |
谭兴贵等: "《中国食物药用大典》", 31 July 2013, 西安交通大学出版社 * |
赵潍: "《防癌抗癌饮食事典》", 30 June 2014, 中国纺织出版社 * |
郭淑英等: "阿里红多糖的提取工艺研究及抗肿瘤作用初探", 《中国卫生检验杂志》 * |
黄红兵: "《抗肿瘤中药临床应用与图谱》", 31 January 2008, 广东科技出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103690646B (zh) | 一种益康补元片的制备方法及其在抑制小鼠淋巴瘤细胞yac-1细胞增殖药物中的应用 | |
CN103655843B (zh) | 一种益康补元片及其制备方法和应用 | |
CN103690647B (zh) | 一种益康补元片的制备方法及其在抑制小鼠白血病细胞l6565细胞增殖药物中的应用 | |
CN104288658A (zh) | 一种阿里红咳喘片的制备方法及其在抑制小鼠骨髓瘤细胞sp2/0 细胞增殖药物中的应用 | |
CN103751424A (zh) | 一种青梅感冒片的制备方法及其在抑制畸胎瘤细胞f9细胞增殖药物中的应用 | |
CN103655841B (zh) | 一种益康补元片的制备方法及其在抑制小鼠淋巴样瘤细胞p388d1细胞增殖药物中的应用 | |
CN103655842B (zh) | 一种益康补元片的制备方法及其在抑制小鼠淋巴瘤细胞el4.il-2细胞增殖药物中的应用 | |
CN103655839B (zh) | 一种益康补元片的制备方法及其在抑制小鼠肺癌细胞llc细胞增殖药物中的应用 | |
CN103768211A (zh) | 一种青梅感冒片的制备方法及其在抑制淋巴瘤细胞el4细胞增殖药物中的应用 | |
CN103800498A (zh) | 一种青梅感冒片的制备方法及其在抑制列腺癌细胞rm-1细胞增殖药物中的应用 | |
CN103893411A (zh) | 一种青梅感冒片的制备方法及应用 | |
CN103768262A (zh) | 一种青梅感冒片的制备方法及其在抑制骨髓瘤细胞fo细胞增殖药物中的应用 | |
CN103768266A (zh) | 一种青梅感冒片的制备方法及其在抑制白血病细胞l6565细胞增殖药物中的应用 | |
CN103768267A (zh) | 一种青梅感冒片的制备方法及其在抑制肝癌细胞h22细胞增殖药物中的应用 | |
CN103705825B (zh) | 铁帚清浊片在制备抑制畸胎瘤细胞f9细胞增殖药物中的应用 | |
CN104288655A (zh) | 一种阿里红咳喘片的制备方法及其在抑制小鼠畸胎瘤细胞f9细胞增殖药物中的应用 | |
CN104288657A (zh) | 一种阿里红咳喘片的制备方法及其在抑制小鼠畸胎瘤细胞p19 细胞增殖药物中的应用 | |
CN104288660A (zh) | 一种阿里红咳喘片的制备方法及其在抑制小鼠淋巴瘤细胞el4 细胞增殖药物中的应用 | |
CN104288654A (zh) | 一种阿里红咳喘片的制备方法及其在抑制小鼠肺癌细胞llc细胞增殖药物中的应用 | |
CN104288653A (zh) | 一种阿里红咳喘片的制备方法及其在抑制小鼠骨髓瘤细胞fo细胞增殖药物中的应用 | |
CN104288659A (zh) | 一种阿里红咳喘片的制备方法及其在抑制小鼠乳腺肿瘤细胞c127 细胞增殖药物中的应用 | |
CN104288656A (zh) | 一种阿里红咳喘片的制备方法及其在抑制小鼠前列腺癌细胞rm-1 细胞增殖药物中的应用 | |
CN103655838B (zh) | 一种益康补元片的制备方法及其在抑制小鼠淋巴瘤细胞l5178y细胞增殖药物中的应用 | |
CN104352927A (zh) | 一种阿里红咳喘片的制备方法及其在抑制小鼠白血病细胞l6565细胞增殖药物中的应用 | |
CN104352931A (zh) | 一种阿里红咳喘片的制备方法及其在抑制小鼠黑色素瘤细胞b16 细胞增殖药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150121 |